Skip to main content
. 2022 Sep 1;25(9):609–616. doi: 10.34172/aim.2022.96

Table 3. Cox Analysis to Assess the Relationship Between Demographic, Clinical and Therapeutic Variables with the Survival of the Participants (n = 3443) .

Predictors Variable Number of Patients Number of Death (%) Hazard Ratio (95% CI)
Univariate Multivariate
Age (y)
 < 50 2078 269 (12.9) 1 -
 ≥ 50 1365 236 (17.3) 1.45 (1.22–1.73)* -
Education level
 ≥ high school diploma 1619 188 (11.6) 1 1
 < high school diploma 1640 291 (17.7) 1.8 (1.5–2.16)* 1.57 (1.13–2.17)*
Marital status
Married 2729 383 (14) 1 1
Single/divorced/ widowed 714 122 (17.1) 1.28 (1.05–1.57)* 1.65 (1.13–2.4)*
Reproductive status
Menopausal 2066 234 (17) 1 -
Premenopausal 1377 271 (13.12) 0.83 (0.7–0.99)* -
Lymph node involvement
Negative 1024 82 (8.01) 1 1
Positive 1834 352 (19.22) 3.03 (2.38–3.85)* 2.07 (1.38–3.09)*
Tumor size (cm)
 < 2 646 43 (6.66) 1 1
2–5 1263 201 (15.91) 2.37 (1.7–3.3)* 1.52 (0.89–2.59)
 ≥ 5 531 140 (26.37) 5.7 (4.04–8.03)* 2.83 (1.59–2.04)*
Type of surgery
Breast preservation 1247 116 (9.3) 1 -
MRM 1582 301 (19) 1.84 (1.49–2.29)* -
Pathology Report
Others 472 45 (9.53) 1 -
Invasive ductal carcinoma 2478 398 (16.06) 1.58 (1.16–2.16)* -
Grading of disease
I 231 30 (12.99) 1 -
II 1202 180 (14.97) 1.17 (0.8–1.73) -
III 582 99 (17.01) 1.55 (1.03–2.23)* -
Estrogen receptor
Positive 1539 236 (15.33) 1 -
Negative 596 112 (18.79) 1.23 (0.98–1.53) -
Her2 receptor
Negative 1238 192 (15.5) 1 -
Others 566 104 (18.4) 1.21 (0.95–1.54) -
Chemotherapy
Yes 2392 391 (16.3) 1 -
No 262 27 (10.3) 0.53 (0.36–0.78)* -
Radiotherapy
Yes 2102 324 (15.4) 1 -
No 334 55 (16.5) 0.85 (0.64–1.13) -
Hormone therapy
Yes 1642 235 (14.3) 1 -
No 218 52 (23.9) 1.48 (1.09–1.99)* -

*Significant statistical correlation (P < 0.05).